Atomo Diagnostics (ASX: AT1)
We spoke with John Kelly, CEO of Atomo Diagnostics (ASX: AT1) about the company’s progress with its new syphilis diagnostic and the building out of its diagnostics pipeline. We also talked about AT1’s continued success with its core HIV diagnostic franchise. Atomo’s diagnostics are highly differentiated from the current standard of care, increasing the coming commercial payoff.
Disclosure: Atomo Diagnostics is a research client of Pitt Street Research. Check out all research on AT1 here!
Looking for the Best ASX Life Sciences stocks to invest in right now?
